Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-16
2005-08-16
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011400, C530S311000
Reexamination Certificate
active
06930088
ABSTRACT:
Novel peptides which are conformationally constrained backbone cyclized somatostatin analogs, having somatostatin receptor subtype selectivity are disclosed. These patterns or receptor subtype selectivity provide compounds having improved therapeutic utility. Methods for synthesizing the somatostatin analogs and for screening of the somatostatin analogs are also disclosed. Furthermore, pharmaceutical compositions comprising somatostatin analogs, and methods of using such compositions are disclosed.
REFERENCES:
patent: 3988304 (1976-10-01), Garsky
patent: 4011182 (1977-03-01), Sarantakis
patent: 4054558 (1977-10-01), Garsky
patent: 4187217 (1980-02-01), Chipens et al.
patent: 4191754 (1980-03-01), Veber et al.
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 4395403 (1983-07-01), Bauer et al.
patent: 5364851 (1994-11-01), Joran
patent: 5371070 (1994-12-01), Koerber et al.
patent: 5770687 (1998-06-01), Hornik et al.
patent: 5811392 (1998-09-01), Gilon et al.
patent: 5874529 (1999-02-01), Gilon et al.
patent: 6051554 (2000-04-01), Hornik et al.
patent: 6355613 (2002-03-01), Hornik et al.
patent: 0 334 244 (1989-09-01), None
patent: 0 336 779 (1989-10-01), None
patent: 0 370 453 (1990-05-01), None
patent: 0 336 779 (1991-08-01), None
patent: 0 564 739 (1993-10-01), None
patent: 0 564 739 (1995-04-01), None
patent: 2304352 (1976-10-01), None
patent: 2411828 (1979-07-01), None
patent: WO 89/01781 (1989-03-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 92/22566 (1992-12-01), None
patent: WO 93/01206 (1993-01-01), None
patent: WO 94/11393 (1994-05-01), None
Arad et al. (including Afargan Gellerman, Hornik). Backbone-cyclic peptides in peptide drug discovery. Book of Abstracts, 211thACS National Meeting, New Orleans, LA, Mar. 24-28 (1996), I & EC-012. American Chemical Society: Washington, D.C.
Kaljuste, et al. A new general solid-phase method for the synthesis of backbone-to-backbone cyclized peptides. Int J Pept Protein Res. May 1994;43(5):505-511.
Bell et al., 1993, “Molecular biology of somatostatin receptors,” TINS, vol. 16, No. 1, 34-38.
Brazeau et al, 1973, “Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreative Pituitary Growth Hormone”, SCIENCE, vol. 179, pp. 77-79.
Buscail et al., 1995, “Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms,” Proc. Natl. Acad. Sci. USA 92: 1580-1584.
Byk et al., 1992, “Building units for N-backbone cyclic peptides. I. Synthesis of protected N-(ω-aminoalkylene)amino acids and their incorporation into dipeptide units”,J. Org. Chem.57:5687-5692.
Charpentier et al., 1989, “Synthesis and binding affinities of cyclic and related linear analogues of CCK8selective for central receptors,” J. Med. Chem., pp. 1184-1190.
Giannis et al., 1993, “Peptidomimetics for receptor ligands—discovery, development, and medical perspectives,” Angew. Chem. Int. Ed. Engl. 32: 1244-1267.
Gilon et al., 1991, “Backbone Cyclization: A New Method for Conferring Conformational Constraint on Peptides”,Biopolymers31:745-750.
Gilon et al., 1992, “SAR studies of cycloseptide: effects of cyclization and charge at position 6,” Chem. Biol. Proc. Am. Pept. Symp 1th. pp. 476-477.
Greiner et al., “Synthesis of New Backbone-Cyclized Bradykinin Analogs”,Proc. Eur. Pept. Symp.,23rd, Meeting Date 1994, 289-290.
Hruby et al., 1990, “Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations,” Biochem. J. 298: 249-262.
Krstenansky et al., 1994, “Cyclic Hexapeptide anatagonists of the bradykinin B2receptor: Receptor binding and solution backbone conformation”,Letters in Peptide Science1:229-234.
Lamberts, 1988, “The role of Somastatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors,” Endocrine Reviews vol. 9, No. 4, pp. 417-436.
Lamberts et al., 1990,“Somastatin-receptor imaging in the localization of endocrine tumors,” New England J. Med. 323:1246-1249.
Lymangrover et al., 1993, “Varying the duration of A23187 administration alters its effect on adrenal steroidogenesis,” Life sciences 34:371-377.
Mosberg et al., 1983, “Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors,” Biochemistry 80:5871-5874.
Plotsky et al., 1985, “Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat,” Science 230:461-463.
Raynor et al., 1993, “Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides,” Mol. pharmacol. 43:838-844.
Reisine et al., 1995, “Molecular biology of somatostatin receptors,” Endocrine reviews 16, 427-442.
Reubi et al., 1995, “Multiple actions of somatostatin in neoplastic disease,” TIPS 16: 110-115.
Rizo et al., 1992, “Constrained peptides: Models of bioactive peptides and protein substructures,” Annu. Rev. Biochem. 61:387-418.
Rodriguez et al. 1990, “Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors,” Int. J. Peptide Protein Res. 35:441-451.
Steranka et al., 1988, “Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions,” Proc. Natl. Acad. Sci. USA 85:3245-3249.
Verber et al., 1984, “A super active cyclic hexapeptide analog of somatostatin,” Life sciences 34:1371-1378.
Verber et al., 1985, “The design of metabolically-stable peptide analogs,” TINS, pp. 392-396.
Zuckerman, 1993, “The chemical synthesis of peptidomimetic libraries,” Current Opinion in Structure Biol., 3: 580-584.
Afargan Michel M.
Gellerman Gary
Hornik Vered
Audet Maury
Peptor Ltd.
Tate Christopher R.
Winston & Strawn LLP
LandOfFree
Conformationally constrained backbone cyclized somatostatin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conformationally constrained backbone cyclized somatostatin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conformationally constrained backbone cyclized somatostatin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3491424